Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.

A Comparison of Antibody Response Against SARS-CoV-2 in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04633915

Acronym

COV-HD

Enrollment

Registered

2020-11-18

Start date

2020-11-26

Completion date

2021-07-18

Last updated

2021-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, Dialysis

Keywords

antibodies, IgG, CKD, hemodialysis

Brief summary

This is prospective cohort study aimed to compare antibody response against SARS-CoV-2 in dialysis patients and non-dialysis-dependent volunteers. The research hypothesis is that dynamic of IgG antibodies against SARS-CoV-2 will differ in two groups. To determine whether there is a statistically significant interaction between factors group and time on the titer of IgG antibodies against SARS-CoV-2, a two-way repeated measures ANOVA will be used.

Detailed description

In both groups level of IgG antibodies against SARS-CoV-2 will be measured at the Day 1 (10 weeks from the date of first symptoms), Weeks 8 and 16 from the Day 1.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Age 18 years or older * SARS-CoV-2 infection within 10 weeks prior enrollment, confirmed by PCR or strongly suspected on computed tomography * Providing informed consent

Exclusion criteria

* Refusal to provide informed consent

Design outcomes

Primary

Measure	Time frame
Anti-SARS-COV-2 IgG level	16 weeks

Secondary

Measure	Time frame
Proportion of people with detectable Anti-SARS-COV-2 IgG in study groups	Day 1, weeks 8, 16
Anti-SARS-COV-2 IgG level	8 weeks

Countries

Russia

Outcome results